Skip to main content

Table 3 Safety results of Hydrus Microstent studies

From: Hydrus microstent implantation for surgical management of glaucoma: a review of design, efficacy and safety

Publication Intervention Hyphema Corneal Pathology Focal PAS/ Iris Adhesions Device Obstruction Device Malposition Laser for PAS/ Iris Adhesion IOP Spike Secondary Surgical Intervention Other
Gandolfi et al. 2016 [45] 21 Hydrus 19.0% 19.0% 4.8% 9.5%
24 Canaloplasty 29.2% 25.0% 12.5% 8.3%
Fea et al. 2017 [46] 92 Hydrus + Phaco 1.1% 8.7% 1.1% 1.1% 1.1% 1.1% Trab CME 1.1%
CRVO 1.1%
Fea et al. 2017 [51] 31 Hydrus 6.4% 3.2% Edema 6.4%
25 SLT Mild eye discomfort 40%
Al-Mugheiry et al. 2017 [52] 25 Hydrus + Phaco 36.0% 28.0% Edema 20.0% 4.0% 4.0% POD1, 20.0% POW1 Anterior uveitis 48.0% POD1, 28.0% POW1
CME 4.0%
Stent-iris touch 4.0%
PCO 16.0%
Pfeiffer et al. 2015 [53] 50 Hydrus + Phaco 2.0% POM1 Descemet folds 12.0% POY1
18.8% POY2
4.0% POY1 2.1% POY2 Mac edema 2.0% POY1
Optic disc hem 2.0% POY1
Vitreal mac traction 2.1% POY2
50 Phaco 2.0% POM1 Descemet folds 2.0% POY1
2.0% POY2
4.0% POY1 4.1% POY2 Mac edema 4.0% POY1
Vitreal mac traction 2.0% POY1
ERM 4.0% POY1, 2.0% POY2
Retinal detachment 2.0% POY1
Wound dehiscence 2.0% POY1
AION 2.0% POY1
Iris erosion 6.0% POM1
Samuelson et al. 2019
[21]
369 Hydrus + Phaco 0.5% 1.4% Edema
1.1% Abrasion
14.9% 3.8%   0.8% 0.5% 0.3% Paracentesis
0.8% Laser membranectomy
Uveitis/iritis 5.6%
Conjunctivitis 5.75%
CME 2.2%
ERM 1.6%
Subconj hem 2.4%
187 Phaco 0.5% 2.1% 2.7% 2.1% Tube shunt/Trab
1.0% Paracentesis
0.5% SLT
Uveitis/iritis 3.7%
Conjunctivitis 7.0%
CME 2.1%
ERM 1.6%
Neovascular glaucoma 0.5%
Ahmed et al. 2019 [56] 75 Hydrus 12.2% 1.3% 4.1% New cataract 2.6%
77, 2 iStent 13.2% 5.2% 2.6% Trab/GDD New cataract 1.3%
Cataract surgery 1.3%
  1. PAS peripheral anterior synechiae, IOP intraocular pressure, CME cystoid macular edema, CRVO central retinal vein occlusion, SLT selective laser trabeculoplasty, PCO posterior capsule opacification, POD1 postoperative day 1, POW1 postoperative week 1, POM1 postoperative month 1, POY1 postoperative year 1, POY2 postoperative year 2, ERM epiretinal membrane, AION anterior ischemic optic neuropathy, mac macular, subconj subconjunctival, hem hemorrhage, Trab trabeculectomy, GDD glaucoma drainage device